Aim: To investigate the mechanisms behind the lower postprandial glucose (PPG) concentrations achieved with fast-acting insulin aspart (faster aspart) than with insulin aspart (IAsp).
compared with IAsp, leading to reduced PPG concentration with faster aspart. 4, [6] [7] [8] [9] The PPG concentration is determined by the rate of appearance of ingested glucose (ie, glucose absorbed from the meal), the rate of endogenous glucose production (EGP; ie, hepatic glucose output) and the rate of glucose disappearance (glucose R d ; primarily muscle glucose uptake). 10 Physiological insulin secretion after a meal in healthy people leads to rapid and profound suppression of EGP combined with increased glucose R d , thereby controlling the temporary rise in glucose concentration. 11 In contrast, people with type 1 diabetes (T1D) lack endogenous insulin, and in people with type 2 diabetes (T2D) postprandial suppression of EGP is slower and the glucose R d is lower for given circulating glucose and insulin concentrations, with both factors contributing to postprandial hyperglycaemia. 12, 13 For mealtime insulins, to ensure the best control of PPG, it would be desirable to replicate the insulin profile in the healthy state, thus ensuring rapid and early stimulation of glucose uptake as well as suppression of EGP.
With the accelerated pharmacokinetic profile of faster aspart, closer to physiological prandial insulin delivery, we hypothesized that the reduced postprandial hyperglycaemia achieved with faster aspart resulted not only from enhanced early stimulation of glucose uptake, but also from greater early inhibition of EGP. To test this hypothesis, in the present study, we investigated the mechanisms behind the improved PPG control with faster aspart vs IAsp, using state-of-the-art triple-tracer methodology to assess PPG turnover. 10, 14 2 | MATERIALS AND METHODS 
| Study design

| Participants
Eligible participants were men and women aged 18 to 64 years, diagnosed with T1D ≥12 months prior to enrolment, treated with multiple daily insulin injections or continuous subcutaneous insulin infusion for ≥12 months (total daily insulin dose <1.2 (I)U/kg/d and total daily bolus insulin dose <0.7 (I)U/kg/d), with a body mass index of 18.5 to 28.0 kg/m 2 , a glycated haemoglobin (HbA1c) concentration ≤ 69 mmol/mol (8.5%), fasting C-peptide concentration ≤ 0.3 nmol/L, and with a current, accurate insulin:carbohydrate ratio (defined as 3-to 4-hour PPG increment) <2.8 mmol/L based on all available (and at least 3) self-measured plasma glucose (PG) values before and after breakfast during the last 10 days prior to screening.
| Procedures
The trial consisted of a screening visit, two dosing visits separated by 3 to 42 days and a follow-up visit. At the two dosing visits, participants received single administration of faster aspart (100 U/mL; Novo Nordisk, Bagsvaerd, Denmark) or IAsp (NovoRapid ® 100 U/mL [Novo Nordisk]) in a randomized sequence. Both trial products were administered subcutaneously into a lifted skin fold of the lower abdominal wall above the inguinal area using a blinded PDS290 peninjector prefilled pen (Novo Nordisk). The dose was individualized (0.06-0.28 U/kg) based on the participant's customary insulin:carbohydrate ratio and was identical at the two dosing visits for each participant.
At each dosing visit, participants received a standardized dinner at 7:00 PM and were subsequently fasting (except for water intake) until the next day's meal test. A glucose target of 5.5 mmol/L was obtained overnight by variable intravenous (i.v.) infusion of regular human insulin (RHI; Actrapid ® , Novo Nordisk) and glucose (10%) starting at 10:00 PM (either insulin or glucose at a given time). The i.v. glucose infusion (if any) was terminated 4 hours prior to the meal test. Water was not allowed within the last 3 hours before the meal test. On the following morning, a 6-hour mixed meal test was conducted and PPG turnover assessed using the triple-tracer method. 10, 14 In brief, at 6:00 AM (3 hours before start of the meal test) a primed, continuous, variable i.v. infusion of [6,6-2 H 2 ] glucose was initiated and continued until end of the meal test. At 9:00 AM, the trial product was administered and immediately thereafter, a stan- Participants did not consume water until 2 hours after dosing (apart from that served with the standardized mixed meal) and did not eat until 6 hours post-dose when they were served meals and snacks. From 6 to 8 hours post-dose, short-acting insulin was limited to RHI.
| Assessments
Fat-free mass was determined by dual-energy X-ray absorptiometry.
Free serum IAsp concentrations (polyethylene glycol precipitated)
were determined using a validated IAsp-specific enzyme-linked immunosorbent assay having a lower limit of quantification (LLOQ) of Safety assessments included adverse events, hypoglycaemic episodes (classified as "severe" according to the American Diabetes Association, ie, requiring third-party assistance, 16 or "confirmed", ie, documented by PG <3.1 mmol/L, with or without symptoms consistent with hypoglycaemia), laboratory safety variables, physical examination, vital signs and ECG.
| Calculations
Baseline and postprandial rates of glucose turnover were calculated as previously described. 14 glucose to [1-13 C] glucose was used to calculate the rate of glucose appearance originating from the meal. The rate of EGP and the glucose R d were then calculated as previously described. 14 
| Endpoints
Pharmacokinetic endpoints to assess onset of exposure and early exposure were defined and derived as previously described. 7 The postprandial PG increment during the meal test was assessed by deriving the mean PG excursion from 0 to 1 hour (ΔPG mean,0-1h ; primary endpoint) and from 0 to 2 hours (ΔPG mean,0-2h ) and the PG excursion at 1 and 2 hours (ΔPG 1h and ΔPG 2h ).
Initial EGP suppression during the meal test was assessed by deriving the mean suppression of EGP during the first 30 minutes, 
| Statistical analysis
Assuming a true treatment difference of 0.85 mmol/L for the primary endpoint, ΔPG mean,0-1h , and a within-participant standard deviation of 1 mmol/L (from a previous trial with faster aspart and IAsp 17 ), 31 completing participants were required to show a statistically significant treatment difference with 90% power when using a two-sided test and a significance level of 5%. In order to take noncompleters into account, 38 participants were planned to be randomized in the trial.
Endpoints were compared between treatments in a linear model, with treatment, period and participant as fixed effects. For analysis of ΔPG mean,0-1h , ΔPG mean,0-2h , ΔPG 1h , ΔPG 2h and ΔAOC FFA,0-1h , the pre-dose value was included as covariate. Early and overall exposure endpoints were log-transformed prior to analysis. For endpoints analysed on the original scale, treatment ratios and 95% confidence intervals (CIs) were calculated by Fieller's method. 18 3 | RESULTS
| Participant disposition and baseline characteristics
A total of 76 individuals were screened, 42 were randomized, and 41 were exposed to the trial products and completed the trial. One participant was withdrawn before exposure because of a lack of PG stabilization before trial product administration. The safety analysis set included the 41 exposed participants. The full analysis set (used for pharmacokinetic analyses) included 40 participants (one participant who received a different dose at the two dosing visits was excluded). Pharmacodynamic analyses included 38 participants (2 participants ingesting a different meal size at the two dosing visits were excluded). Participant disposition is presented in Figure S1 . Participant characteristics are shown in Table 1 .
| Pharmacokinetics
The mean pharmacokinetic profile was shifted to the left for faster aspart vs IAsp ( Figure 1A) . Accordingly, faster aspart provided earlier onset of exposure as well as greater initial exposure after subcutaneous administration compared with IAsp. Thus, shorter t Early 50% Cmax (by 9 minutes; P < .001) and earlier t max (by 19 minutes; P < .001) were seen with faster aspart vs IAsp ( Table 2) . Early exposure within the first 2 hours after administration was statistically significantly greater for faster aspart vs IAsp (Figure 2 ). During the first 15, 30 and 60 minutes after administration, respectively,~3.7-fold greater, 2-fold greater and 32% greater insulin exposure was seen with faster aspart than with IAsp (P < .001).
Total exposure (AUC IAsp,0-t ) and maximum concentration (C max ) were similar for faster aspart and IAsp. LS means (betweenparticipant coefficient of variation in %) for AUC IAsp,0-t were 370 pmolÁh/L (1%) and 378 pmolÁh/L (1%) for faster aspart and IAsp, respectively (estimated ratio faster aspart/IAsp 0.98 [95% CI 0.95;1.01]; P = .141). LS means for C max were 171 pmol/L (3%) and 162 pmol/L (3%) for faster aspart and IAsp, respectively (1.06 [95% CI 0.97; 1.15]; P = .190).
| Pharmacodynamics
Glucose intervention with a dextrose drink (labelled with [1- 13 Over the first 2 hours of the meal test, an apparently smaller increase in PG was seen for faster aspart vs IAsp, with the greatest difference observed during the first hour ( Figure 1B) . ΔPG mean,0-1h (primary endpoint) and ΔPG 1h showed trends towards a greater reduction with faster aspart than with IAsp ( Table 2) . ΔPG mean,0-2h and ΔPG 2h did not differ statistically significantly between faster aspart and IAsp.
Mean profiles of tracer-to-tracee ratios for [6-3 H] glucose/ Abbreviations: BMI, body mass index; HbA1c, glycated haemoglobin; n, number of subjects; T1D, type 1 diabetes. Data are mean (SD) unless otherwise stated. Plasma glucagon concentration over the first 2 hours of the meal test is presented in Figure 1D , indicating a slightly lower level of circulating glucagon from~15 minutes until 1 hour after meal ingestion for faster aspart vs IAsp.
| Safety
Faster aspart and IAsp were well tolerated, and no safety issues were identified. A total of 6 adverse events (5 after faster aspart and 1 after IAsp) were reported in 5 participants, which were mainly of mild intensity and were assessed to be unrelated to the trial product. All participants recovered from the events. There were no serious adverse events. A total of 6 confirmed hypoglycaemic episodes (1 after faster aspart and 5 after IAsp) were reported in 6 participants (none were severe and none occurred within the first 2 hours 
| DISCUSSION
To the best of our knowledge, the present trial is the first to compare PPG fluxes between two exogenous short-acting insulin products with different pharmacological profiles. Since the pharmacological profiles of faster aspart and IAsp are known to differ mainly within the first 1 to 2 hours after administration, 6 the present trial focused on that time period. The main finding was that within the first hour of meal ingestion, faster aspart administration led not only to higher glucose R d but also to greater suppression of EGP compared with IAsp. These effects of faster aspart on glucose turnover collectively resulted in a trend towards a reduced PPG increment with faster aspart vs IAsp. Thus, the present trial provides the mechanism(s), regarding glucose fluxes, behind the reduction in PPG increment with faster aspart compared with IAsp shown in recent clinical trials in individuals with T1D and T2D. 8, 9 The relative contributions from treatment differences in postprandial glucose R d and EGP suppression to the smaller ΔPG 1h with faster aspart were not directly estimated in the present trial; however, it can be inferred by comparison of the areas between the curves in Figures S4 and S5 that the increased stimulation of glucose R d with faster aspart vs IAsp was the most important contributor to the treatment difference in ΔPG 1h . Nevertheless, the finding of greater early EGP suppression with faster aspart vs IAsp is highly interesting. Exogenous insulin products administered subcutaneously are likely to shift the normal hepatic to peripheral insulin gradient, thereby causing relative peripheral hyperinsulinaemia and underinsulinization of the liver. 19 It is therefore reassuring that part of the improved PPG control with faster aspart is attributable to effects exerted on the liver which may, at least partly, be attributable to greater early suppression of postprandial circulating FFA concentration, another finding in the present trial ( Figure 1C ). While comparison of glucose turnover results between studies are fraught with considerable limitations, it is intriguing that the earlier exposure to insulin with faster aspart still does not fully restore insulin stimulation of glucose R d nor insulin suppression of EGP to the rates observed in healthy individuals without diabetes. 13 The maximum postprandial EGP suppression of 68% is in line with previous findings. 20 The regulation of postprandial EGP suppression is complex and depends mainly on circulating insulin, glucose and glucagon concentrations. 21 This may explain why some variability in EGP between two consecutive mornings has been found in individuals with T1D. 22 In the present trial, however, the greater postprandial EGP suppression with faster aspart vs IAsp was sufficiently robust to show statistically significant differences at all three time periods assessed ( Figure 3A) .
Although the accelerated pharmacokinetic profile of faster aspart vs IAsp was presumably the primary reason for the greater early postprandial EGP suppression with faster aspart, other indirect factors may also have played a role. In patients with T1D, the lack of contrary to what is seen in healthy individuals. 23 It has been shown both in T1D and T2D that lack of postprandial suppression of glucagon contributes to hyperglycaemia via elevated hepatic glucose release. 24, 25 In the present trial, the postprandial increase in glucagon was slightly less for faster aspart than for IAsp ( Figure 1D ), which may have contributed to the greater EGP suppression with faster aspart; however, given that individual plasma glucagon concentrations were below the LLOQ at several time points, as mentioned earlier, we cannot be certain of the contribution of lower plasma glucagon concentrations on EGP with faster aspart. Furthermore, the lower postprandial circulating FFA concentration with faster aspart vs IAsp may have improved the ability of insulin to suppress EGP and may also have reduced the availability of FFA to the liver, thereby limiting FFA oxidation and thus the rate of gluconeogenesis. 21 The fraction of glucose derived from the meal, taken up by the liver during the first pass from the gut via the portal vein into the sys- Figure S3 ) and beyond (data not shown), the first-pass hepatic glucose uptake was also most likely similar for faster aspart and IAsp, and therefore apparently not influenced by the faster onset and greater early exposure seen with faster aspart.
The most important strength of the present trial was the use of the triple-tracer technique, which limited non-steady-state errors by minimizing changes in the tracer-to-tracee ratios used to measure meal glucose rate of appearance and EGP. 10, 14 As shown in Figure S2 , the ratio of [6,6-2 H 2 ] glucose to endogenous glucose was constant and unchanging throughout the duration of the experiment during both study visits, thereby implying that the rates of calculated EGP are robust. However, as has been observed in prior triple-tracer meal studies, the ratio of [6-3 H] glucose to [1-13 C] glucose, used to calculate meal glucose rate of appearance, varied for the first 30 minutes after meal ingestion, then became relatively smooth for the next 2 hours before gradually rising for the rest of the experiment congruently during both study visits. The imprecision of measurement of meal glucose rate of appearance for the initial postprandial period, therefore, appears to be similarly affected during both study visits. Still, the nonsteady-state situation early after meal ingestion and insulin administration, together with a minor transient increase in EGP, implied that it was not valid to derive endpoints related solely to very early EGP suppression (up to 15 minutes) and glucose R d (up to 30 minutes).
Another strength was the use of an individualized prandial insulin dose, thereby reflecting clinical practice. While the current highly standardized experimental setup ensured robust conclusions on the mechanisms behind the trend towards a lower PPG increment with faster aspart, it could also be a limitation. For example, the standard mixed meal ingested by all participants puts certain limitations on the clinical applicability of the results. Along these lines, the present findings should also be interpreted in light of the fact that the reduction in PPG increment with faster aspart vs IAsp in the present trial (−0.59 mmol/ L) was less than observed in a recent phase III trial in participants with T1D (−1.18 mmol/L). 8 The present study was conducted in participants with T1D. Using the triple-tracer technique in participants with T2D, we have previously demonstrated significant postprandial hepatic and peripheral insulin resistance in these individuals. 13 Future studies are therefore necessary in insulin-requiring people with T2D to determine the extent to which, if at all, faster aspart alters insulin suppression of EGP and stimulation of glucose R d in that population.
In conclusion, in line with previous findings, the present trial showed that faster aspart provides earlier onset of exposure and greater early exposure compared with IAsp, which in the present study, led to a trend towards improved 1-hour PPG control with faster aspart. This trend was attributable to greater suppression of EGP as well as higher glucose R d with faster aspart vs IAsp.
